This Article Full Text (PDF) All Versions of this Article: theoncologist.2009-0195v1 14/11/1083    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Bugalho, M. J. Articles by Borges, A. PubMed PubMed Citation Articles by Bugalho, M. J. Articles by Borges, A.

Case Report: A Case of Advanced Medullary Thyroid Carcinoma Successfully Treated with Sunitinib

^aServiço de Endocrinologia, ^bCentro de Investigação de Patobiologia Molecular, and ^dServiço de Radiologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal; ^cClínica Universitária de Endocrinologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal

Key Words. Sunitinib • Thyroid • Carcinoma

Correspondence: Correspondence: Maria João Bugalho, M.D., Ph.D., Serviço de Endocrinologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Rua Professor Lima Basto, 1099-023, Lisboa, Portugal. Telephone: 351-217229818; Fax: 351-217229895; e-mail: mjbugalho{at}ipolisboa.min-saude.pt

Received August 23, 2009; accepted for publication October 13, 2009.

Maria João Bugalho: None; Rita Domingues: None; Alexandra Borges: None. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers. The article discusses sunitinib (Pfizer) for the treatment of medullary thyroid carcinoma.

Context. Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from "C" cells of the thyroid; it is a RET associated cancer that can be sporadic or familial in origin. Advances in understanding the genetic changes associated with the development of MTC explain the growing interest in the therapeutic potential of tyrosine kinase inhibitors. Sunitinib is an orally administered multikinase inhibitor likely to target multiple pathways in the tumor, stromal, and endothelial compartments. Its role in the treatment of MTC patients has not yet been established.

Objective. To present the case of a patient with a sporadic and unresectable MTC who was successfully treated with sunitinib.

Patient and Results. A 55-year-old man with locally advanced MTC, without germinal and/or somatic RET mutations, was started on sunitinib (50 mg/day for 28 days, followed by 14 days of no treatment). At the time of writing, he had received four consecutive cycles. At the end of the first cycle, his serum calcitonin level had dropped by 81%. In the following cycles, a long-lasting minor response was observed. An early and dramatic tumor reduction, particularly of a cervical lymph node conglomerate, was observed and confirmed by the Response Evaluation Criteria in Solid Tumors.

Conclusion. Sunitinib may play a role in the management of patients with locally advanced MTC or distant metastatic disease, for which no effective systemic therapy exists. Moreover, the absence of RET mutations does not seem to be an exclusion criterion for sunitinib treatment.

This article has been cited by other articles:

				A. Ravaud, C. de la Fouchardiere, J. Asselineau, J.-P. Delord, C. Do Cao, P. Niccoli, P. Rodien, M. Klein, and B. Catargi Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU Oncologist, February 1, 2010; 15(2): 212 - 213. [Full Text] [PDF]

				M. J. Bugalho In Reply Oncologist, February 1, 2010; 15(2): 214 - 214. [Full Text] [PDF]